220P Elacestrant vs fulvestrant or aromatase inhibitor (AI) in phase III trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), vs standard of care (SOC) endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC): Subgroup analysis from EMERALD

P.G Aftimos,J Sohn,D Taylor,P Dillon,J Lu,A Montero,F.C Bidard,J Kocsis,M.A Mouret Reynier,K Harnden,V Kaklamani V Kaklamani,G Streich,F Dalenc,K.J Grzegorzewski,P Neven,J Cortés,G Tonini,A Bardia,F Forget,H Khong

doi:10.1016/j.annonc.2022.07.259

220P Elacestrant vs fulvestrant or aromatase inhibitor (AI) in phase III trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), vs standard of care (SOC) endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC): Subgroup analysis from EMERALD

P.G Aftimos, J Sohn + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.259

Copy DOI

Journal: Annals of Oncology	Publication Date: Sep 1, 2022
Citations: 4	License type: publisher-specific-oa

Affiliation: Institut Jules Bordet, Yonsei University, CHU Dinant Godinne UCL Namur, University of Virginia, University of Southern California, University Hospitals of Cleveland, Case Western Reserve University, Institute Curie, Bács-Kiskun Megyei Kórház, Centre Jean Perrin, The University of Texas Health Science Center at San Antonio, Argerich Hospital, Institut Claudius Regaud, Ark Therapeutic (United States), Silicon Labs (United States), Massachusetts General Hospital, Harvard University, Moffitt Cancer Center

#Oral Selective Estrogen Receptor Degrader #Selective Estrogen Receptor Degrader + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

The EMERALD clinical trial showed significantly prolonged progression-free survival (PFS) and a manageable toxicity profile for elacestrant vs SOC endocrine therapy in patients (pts) with ER+/HER2- mBC following progression on prior endocrine and CDK4/6 inhibitor therapy. Benefit was observed in the overall population and in pts with ESR1 mutations (mESR1). Here, we report a subgroup analysis from EMERALD comparing efficacy with elacestrant to fulvestrant or AI.

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.